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Abstract
Background: Improving access to parasitological diagnosis of malaria is a central strategy for control and elimination
of the disease. Malaria rapid diagnostic tests (RDTs) are relatively easy to perform and could be used in primary level
clinics to increase coverage of diagnostics and improve treatment of malaria.
Methods: A cost-effectiveness analysis was undertaken of RDT-based diagnosis in public health sector facilities in
Afghanistan comparing the societal and health sector costs of RDTs versus microscopy and RDTs versus clinical
diagnosis in low and moderate transmission areas. The effect measure was ‘appropriate treatment for malaria’
defined using a reference diagnosis. Effects were obtained from a recent trial of RDTs in 22 public health centres
with cost data collected directly from health centres and from patients enrolled in the trial. Decision models were
used to compare the cost of RDT diagnosis versus the current diagnostic method in use at the clinic per appropriately
treated case (incremental cost-effectiveness ratio, ICER).
Results: RDT diagnosis of Plasmodium vivax and Plasmodium falciparum malaria in patients with uncomplicated febrile
illness had higher effectiveness and lower cost compared to microscopy and was cost-effective across the moderate
and low transmission settings. RDTs remained cost-effective when microscopy was used for other clinical purposes.
In the low transmission setting, RDTs were much more effective than clinical diagnosis (65.2% (212/325) vs 12.5%
(40/321)) but at an additional cost (ICER) of US$4.5 per appropriately treated patient including a health sector cost
(ICER) of US$2.5 and household cost of US$2.0. Sensitivity analysis, which varied drug costs, indicated that RDTs
would remain cost-effective if artemisinin combination therapy was used for treating both P. vivax and P. falciparum.
Cost-effectiveness of microscopy relative to RDT is further reduced if the former is used exclusively for malaria diagnosis.
In the health service setting of Afghanistan, RDTs are a cost-effective intervention compared to microscopy.
Conclusions: RDTs remain cost-effective across a range of drug costs and if microscopy is used for a range of diagnostic
services. RDTs have significant advantages over clinical diagnosis with minor increases in the cost of service
provision.
Trial Registration: The trial was registered at ClinicalTrials.gov under identifier NCT00935688.
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Background
Improving access to parasitological malaria diagnosis is a
central strategy for control and elimination of the dis-
ease and is recommended before anti-malarial treatment
in all suspected malaria cases [1,2]. Outside most of sub-
Saharan Africa, diagnosis needs to differentiate between
Plasmodium vivax and Plasmodium falciparum because
treatment differs between the two species. Diagnosis in
most primary level clinics in south and west Asia relies
either on symptoms and signs alone or on microscopy
[3,4]. Both of these methods have significant drawbacks:
symptoms and signs are indistinguishable from other
causes of fever [5] and cannot differentiate between spe-
cies, while microscopy is often inaccurate under field
conditions, hard to maintain, requires skilled staff and
can suffer from a tendency by health providers to treat
patients with negative test results [6-10].
Rapid diagnostic tests (RDTs) for malaria are a poten-
tial alternative to both clinical and microscopy-based
diagnosis since the former are easier to perform, require
limited training and have high accuracy both under con-
trolled and field conditions [2,11-13]. Research from dif-
ferent settings in Africa and Asia suggests that RDTs
have a significant advantage over presumptive diagnosis
and equal or better performance than light microscopy
under field conditions [3,9,14-16]. Almost all studies in-
dicate that RDTs improve appropriate malaria treatment
(interpreted as prescribing anti-malarials only to those
patients with malaria parasites) when compared to pre-
sumptive diagnosis. However, the advantage of RDTs
over microscope diagnosis is typically smaller or insig-
nificant [17,18]. Fewer studies on operational issues of
malaria diagnostics have been performed in west and
south Asia where in excess of 1.5 billion people live in
areas of malaria risk, and vivax malaria is the predomin-
ant species. In Afghanistan, the introduction of malaria
RDTs with relatively simple training in lower level health
centres was found to increase the proportion of patients
appropriately treated for malaria as compared to pre-
sumptive diagnosis and microscopy [3]. The effect was
particularly strong for the detection and treatment of
cases of P. falciparum malaria when relatively rare.
An important consideration for selecting malaria diag-
nostic methods within health systems is the comparative
cost-effectiveness. Assessment of cost-effectiveness pro-
vides data on the costs and sustainability of programmes,
which is particularly important to policy makers when
countries are considering elimination of malaria; in the
later stages of elimination, very few malaria cases will be
found, but facilities must continue to provide malaria
diagnosis to maintain suitable levels of surveillance.
Analyses from African settings suggest that the intro-
duction of malaria diagnosis by falciparum-specific RDT
is likely to be a cost-effective intervention compared to
presumptive diagnosis [19-23], while the cost-effectiveness
advantage of RDTs over microscopy tends to be smaller or
insignificant [23-27]. However, cost-effectiveness depends
critically on a range of factors, including malaria transmis-
sion intensity, health workers’ adherence to test results
when providing treatment, and the underlying costs and
accuracy of the parasitological tests [19,20,22,24-26].
Most of these factors differ between Africa (where the
majority of studies have been undertaken) and south and
central Asia where no studies have examined the cost-
effectiveness of malaria diagnostics. In particular, malaria
transmission is generally much lower in south and cen-
tral Asia and P. vivax is the dominant species [4]. This
increases the cost of tests, which have to be able to detect
two species, whilst reducing the number of true cases.
Only a few studies have been conducted in areas endemic
for both P. falciparum and P. vivax, in Southeast Asia and
the Pacific. A cost-effectiveness analysis was undertaken
to assess the cost-effectiveness of current diagnostic
methods (presumptive or microscopy) with RDT diagnosis
in two different epidemiological settings within the con-
text of a randomized, controlled trial in Afghanistan [3].
Ethical approval
The trial protocol was approved by the Institutional
Review Board of the Ministry of Public Health, Islamic
Republic of Afghanistan (No. 112453) and by the ethics
review board of the London School of Hygiene and
Tropical Medicine (No. 5386).
Methods
Cost-effectiveness analyses of malaria diagnostic methods
from a health sector and societal perspective were con-
ducted in two regions of Afghanistan with different trans-
mission levels. The purpose of these analyses was to
determine if diagnosis by RDT would be a better use of
scarce resources than the malaria diagnostic methods
currently in use in the public health care sector in
Afghanistan. In order to investigate this purpose, incre-
mental cost-effectiveness analysis was used, which by def-
inition is the ratio between the difference in cost if a new
health intervention replaces the intervention currently in
place and the difference in effect when the current inter-
vention is replaced by the new.
Currently, the health sector relies on microscopy and
clinical diagnosis. Incremental cost-effectiveness analyses
were performed for replacing microscopy diagnosis with
RDT and also for introducing RDT diagnosis instead of
clinical diagnosis. These incremental cost-effectiveness
analyses were undertaken using a decision model where
all necessary inputs on costs, effects and probabilities were
obtained from data collection conducted in Afghanistan
during 2009–2012.
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Study setting
Malaria transmission in Afghanistan varies considerably
by area ranging from moderate to very low. Plasmodium
vivax is by far the most common species accounting for
at least 90% of malaria cases annually while P. falcip-
arum is responsible for the remaining malaria infections
[4]. For the trial, one moderate transmission province in
the east adjoining Pakistan and a low transmission prov-
ince in the north bordering Tajikistan were chosen.
Three distinct malaria diagnostic settings were identified:
(1) In the moderate transmission province, light micros-
copy had been a routine component of the services in
public health centres for many years and microscopists
performed malaria microscopy as well as a range of
other diagnostic tests; (2) in the low transmission prov-
ince, new light microscopes had recently been intro-
duced in some health centres with the focus exclusively
on providing malaria parasitological diagnosis and at the
time of the study, the microscopes were not used for any
other diagnostic investigations; and, (3) the remaining
health centres in the same low transmission area did not
have any microscopy capabilities so clinicians diagnosed
malaria based on clinical signs and symptoms alone.
According to national treatment guidelines patients with
microscopy or RDT confirmed Plasmodium vivax receive
chloroquine (25 mg/kg in divided doses over 3 days);
with P. falciparum or mixed infections receive artemisinin
combination therapy (4 mg/kg/day artesunate for 3 days
and a single administration of 25/1.25 mg/kg sulfadoxine-
pyrimethamine on day 1); and clinically diagnosed patients
with suspected malaria receive combination therapy with
sulfadoxine-pyrimethamine (25/1.25 mg/kg on day 0) and
chloroquine (10 mg/kg on days 0 and 1 and 5 mg/kg on
day 2).
Interventions
The intervention assessed in this study was the introduc-
tion of malaria RDTs which were able to distinguish
P. falciparum from other Plasmodium species (Access-
Bio CareStart malaria RDT Pf (HRPII)/Pan (pLDH))
compared to standard care in each setting as described
above. A total of 12 health centres with long-established
microscopy were selected for this study from the moder-
ate transmission area, while ten health centres from the
low transmission area were chosen, five of which had
newly established microscopy focusing on malaria only
while the other five used presumptive malaria diagnosis.
The clinics were purposively selected if they were in se-
cure and accessible areas, and treated malaria or sus-
pected malaria cases. The clinics were typical of the Afghan
health system’s lower tiers defined as Basic Health Centres
or Comprehensive Health Centres [28,29] and were over-
seen and managed by non-governmental organisations.
Measurement of effect
Suspected malaria patients visiting study health centres
and giving consent to participate in this study were
randomized to either a RDT or the currently used diag-
nostic method at the particular health centre. Between
September 2009 and September 2010, a total of 5,749
patients were enrolled [3]. The measure of effect for the
diagnostic interventions was appropriate treatment of
suspected malaria. Appropriate treatment was assessed
against a reference diagnosis and matched the national
malaria treatment guidelines. This was defined as pa-
tients with P. vivax prescribed with chloroquine, patients
with P. falciparum prescribed with artemisinin combin-
ation therapy (ACT) and malaria negative patients not
receiving an anti-malarial. The reference diagnosis was
based on PCR-confirmed, double-read thick and thin
Giemsa-stained blood slides from all patients enrolled in
the trial [3]. The main results, describing full details of
the trial, including the effect of each diagnostic tech-
nique in the different settings on appropriate treatment
of malaria have been published previously [3]. Results
are summarized in Table 1.
Measurement of cost
Costs per service in the public sector for a diagnosis by
microscopy and RDT and treatment for malaria and
non-malarial febrile illnesses were estimated based on
data collected from the non-governmental organizations
that managed the health centres in the study area in
2010. Three health centres in the moderate transmission
east region were excluded due to security problems and/
or gaps in the data collected. At each of the remaining
19 health centres, total recurrent expenditure for the
financial year 2009 were obtained incorporating cost
categories, including salaries of all personnel, medicines,
consumables, utilities, maintenance, cleaning materials,
domestic expenses, etc. Construction cost of health centre
buildings was estimated by obtaining a plan of a typical
basic and comprehensive health centre in Afghanistan as
well as construction cost per square metre from the non-
governmental organizations. An inventory of equipment
and furniture by room in the health centres was done and
each item was subsequently valued by their 2009 purchase
prices. Since buildings, equipment and furniture had a
useful lifespan longer than one year, equivalent annual
cost of the total costs of these inputs were estimated using
a standard annualization procedure with a discount rate
of 0.03 and expected life spans of 20 years for buildings
and seven years for equipment and furniture [30].
These aggregate health centre level costs for 2009 were
then allocated to patient services offered at the health
centres using the standard step-down costing method
[30,31]. This method allocates aggregate cost by category
to overhead and intermediate services and finally to
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patient services in a step-wise fashion using allocation
criteria reflecting actual resource use. For instance, total
salary cost was allocated to relevant services based on
discussions with key personnel on how they spend a
typical day across services.
The step-down costing method was supplemented by
micro-costing methods [32,33] in order to separate out
specifically the cost of services relevant for this study, in-
cluding malaria microscopy and RDT diagnosis in the la-
boratories (or dedicated rooms) and treatment of malaria
and non-malaria fevers in the treatment rooms. A labora-
tory scientist (AM) specified the types and amounts of
reagents and disposables required to perform one malaria
blood slide and similarly for an RDT. For the health cen-
tres in the moderate transmission eastern region, the an-
nual equivalent cost of the microscope was divided
between malaria slide diagnostics and other microscope-
based tests according to relative use. In the low transmis-
sion northern region, the microscope was only used for
investigating malaria blood smears so the whole annual
equivalent cost of a microscope was allocated to malaria
microscopy. Microscopists in the health centres were
asked to estimate the time required to prepare a malaria
slide followed by searching for parasites using the micro-
scope and to perform an RDT, respectively. In some of the
health centres, the activity data collected suggested that
microscopists on average had time available after having
finalized the tests required for a day. In these health cen-
tres, the personnel time and consequently the cost per test
was adjusted upwards to capture this opportunity cost of
available time.
Malaria and non-malarial febrile illnesses were treated
in the consultation room of the health centre. Assuming
that clinicians generally followed official clinical guide-
lines, the doses for treatment of a child and an adult
with malaria specified in these guidelines and prices
from medical stores in Afghanistan were used to esti-
mate the cost per course of ACT (artesunate/sulphadox-
ine-pyrimethamine (SP)) for treating falciparum malaria
and chloroquine (and in some instances including SP)
for treating vivax malaria. Cost per course of antibiotic
treatment for non-malarial febrile illnesses was calcu-
lated using the same method. These drug costs were
adjusted upwards to include the cost of running the
pharmacy/dispensary at the health centres, which had
been captured as part of the standard step-down costing
methodology. Finally, doctors and nurses working in the
consultation rooms were asked to estimate the required
average time used for an outpatient department visit,
including taking illness history and prescribing drugs,
which were subsequently utilized for estimating salary
cost per patient visit based on salary level by personnel
category.
The combination of the step-down and micro-costing
methodologies enabled the estimation of a comprehensive
cost per service in 19 health centres by malaria diagnostic
method and treatment incorporating both immediate
resources such as drugs, disposables and personnel time,
but also shared resources such as administration of the
health centre, security, buildings and equipment. The re-
sults of the health services costing exercise are presented
separately for each region in Tables 2 and 3.
Household cost of healthcare seeking was captured in a
sample of 676 suspected malaria patients (508 in the mod-
erate transmission and 168 in the low transmission region)
for a 28-day period starting from the day a patient first
Table 1 Effects of malaria diagnostic methods on appropriately treated patients in two regions of Afghanistan, 2009
Moderate transmission region Low transmission region
Area with microscopes Area without microscopes
Effects Microscopy arm RDT arm Microscopy arm RDT arm Clinical arm RDT arm
Fever patients suspected of malaria (N) 1,983 2,028 515 523 321 325
Of which suffering from (%)#:
vivax malaria 21.9 19.5 1.0 0.4 0.0 0.0
falciparum malaria 3.8 3.4 0.0 0.0 0.0 0.0
Mixed vivax-falciparum infections 0.1 0.1 0.0 0.0 0.0 0.0
Non-malarial febrile illness 74.3 77.0 99.0 99.6 100.0 100.0
Effect:
Patients appropriately treated (N) 1,512 1,696 393 420 40 212
Patients appropriately treated (%) 76.2 83.6 76.3 80.3 12.5 65.2
Adjusted& odds ratio 1 1.70** 1 1.73* 1 92.7**
(95% CI) (1.30; 2.23) (1.08; 2.78) (12.4; 694.1)
# According to the malaria reference diagnosis.
& Adjusted odds ratio using three level model, adjusted for fixed effect of patient’s age and clinic type (in moderate transmission region) and random effects of
clinician (within clinics) and clinic (between clinics).
* p < 0.05, ** p < 0.001.
Source: [3].
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sought care at one of study health centres. Patients from
the main trial were randomly selected to participate in the
household cost component which involved being inter-
viewed on the day of the first visit to a study health centre
and subsequently receiving a visit in their homes by a
trained interviewer on day 7, day 14 and day 28 after the
initial health centre visit. When leaving the health centre
after the initial visit, these patients were interviewed to
capture information on their out-of-pocket expenditure
for transport, drugs, consultation fees, laboratory fees, or
special foods incurred in relation to the present visit. The
purpose of all the subsequent home visits was to find out
from the patient if there had been any additional treat-
ment seeking to any kind of health provider since the pre-
vious interview and if yes, information was captured on
the same categories of out-of-pocket expenditure. In pub-
lic sector clinics, no fees for consultation, drugs or diag-
nostics are paid so these costs were captured as part of
the facility costing above. In addition, all interviews in-
quired if the fever illness had resulted in days where the
patient and the main caregiver were unable to perform
their normal activities and how much time had been spent
travelling to and waiting at health providers. This oppor-
tunity cost of time lost was valued at GDP per capita per
day in 2009 [34], which amounted to US$1.23 per day.
Household costs are displayed in Tables 2 and 3.
Finally, the costs of RDT and microscopy training for
health workers were included and classified as health
sector cost (Tables 2 and 3). RDT training was minimal
but realistic, to reflect feasibility of implementation at
scale, and therefore expected to be a one-day workshop
occurring every five years. Microscopy refresher training
currently lasts three days and training is envisaged every
three years within a standard quality assurance system.
Refresher training costs included per diem and transport
of trainers and participants, workshop materials and re-
freshments. Costs of the initial training of microscopists
were not included.
Decision analysis
A decision tree was constructed for the control and inter-
vention arms in the three diagnostic settings to compare
Table 2 Cost per unit of health service in study health centres and household cost per treatment seeking episode,
moderate transmission region of Afghanistan, cost in US$ (AFN50.33 = US$1), 2009
Mean Median Minimum Maximum IQR
Health sector cost per service in US$ #
Microscopy 1.89 1.87 1.61 2.21
Rapid diagnostic test 1.92 1.97 1.63 2.23
Outpatient visit excl drugs 0.47 0.43 0.37 0.64
Artimisinin-based combination therapy (SP/AS), adult course 1.14 1.14 1.10 1.19
Artimisinin-based combination therapy (SP/AS), child course 0.65 0.65 0.63 0.68
Chloroquine, adult course 0.14 0.14 0.13 0.14
Chloroquine, child course 0.06 0.06 0.06 0.07
Sulphadoxine-pyrimethamine, adult course 0.14 0.14 0.13 0.14
Sulphadoxine-pyrimethamine, child course 0.06 0.06 0.06 0.07
Antibiotics, adult course 0.14 0.14 0.13 0.14
Antibiotics, child course 0.14 0.14 0.13 0.14
Diagnostics training cost in US$ for health personnel per patient enrolled
Microscopy 0.10
Rapid diagnostic test 0.03
Household cost in US$ (over a period of 28 days from the first visit) &
Out-of-pocket expenditure, patient appropriately treated 3.77 0.00 0.00 129.15 (0.00; 0.00)
Out-of-pocket expenditure, patient inappropriately treated 6.92 0.00 0.00 116.11 (0.00; 1.64)
Opportunity cost of time lost, patient appropriately treated 1.71 0.00 0.00 25.93 (0.00; 2.47)
Opportunity cost of time lost, caregiver of patient appropriately treated 0.65 0.00 0.00 16.05 (0.00; 0.00)
Opportunity cost of time lost, patient inappropriately treated 2.67 0.00 0.00 19.75 (0.00; 3.70)
Opportunity cost of time lost, caregiver of patient inappropriately treated 0.98 0.00 0.00 9.88 (0.00; 1.23)
# Incorporates the full cost of offering services at public health centres including prices of RDTs, microscopy consumables or drugs as well as personnel,
dispensing, utilities, and capital cost of buildings and equipment.
& Lost time valued at US$1.23 per day equal to GDP per capita per day in 2009 [34].
IQR = interquartile range.
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the different possible series of pathways leading to the tri-
al’s primary endpoint of a febrile patient being appropri-
ately treated (Figure 1). Arriving at a health centre, febrile
patients either had malaria (P. falciparum or P. vivax) or a
non-malarial febrile illness (NMFI) as determined by their
reference diagnosis. Each patient was then given a blood
test or clinically diagnosed at the health centre depending
on study arm and diagnostic setting. Healthcare personnel
either complied or did not comply with the diagnostic test
result and subsequently decided on the medical treatment.
The probabilities assigned to each decision tree branch
relating to malaria status according to reference slide,
clinic diagnosis accuracy and drug prescription behav-
iour of health personnel were obtained from the trial [3]
and are reproduced in Additional file 1. The mean costs
of health services obtained from study health centres
and household costs (Tables 2 and 3) were also assigned
to the relevant branches of the trees. The expected costs
and effects associated with each diagnostic test or clin-
ical diagnosis were then calculated by ‘rolling back’ the
decision tree along the branches. Thus, the incremental
cost per additional febrile patient appropriately treated
of the alternative option could be compared.
Probabilistic sensitivity analysis
The uncertainty surrounding the cost-effectiveness re-
sults was assessed through probabilistic sensitivity ana-
lysis (PSA) [35-37]. Distributions were assigned to all
relevant parameters in order to build into the decision
model the combined implications of uncertainty sur-
rounding each of the model inputs. Details are shown in
Additional file 1. Probabilities can necessarily only take
values between zero and one. Beta distributions were fit-
ted when decision nodes had two branches. Other nodes
had multiple branches, including diagnostic accuracy
and treatment, and Dirichlet distributions were fitted to
ensure that mutually exclusive event probabilities summed
to one [38]. Gamma distributions were fitted to household
costs given the skewed nature of the data [35]. Monte
Carlo simulation was used to propagate uncertainty by
randomly selecting values from each parameter’s distribu-
tion by running 1,000 iterations. The generated results of
Table 3 Cost per unit of health service in study health centres and household cost per treatment seeking episode, low
transmission region of Afghanistan, cost in US$ (AFN50.33 = US$1), 2009
Mean Median Minimum Maximum IQR
Health sector cost per service in US$ #
Microscopy 8.32 7.99 6.92 9.89
Rapid diagnostic test 1.30 1.31 1.28 1.33
Outpatient visit excl drugs 0.37 0.40 0.26 0.45
Artimisinin-based combination therapy (SP/AS), adult course 1.28 1.28 1.21 1.42
Artimisinin-based combination therapy (SP/AS), child course 0.73 0.73 0.69 0.81
Chloroquine, adult course 0.16 0.15 0.15 0.17
Chloroquine, child course 0.07 0.07 0.07 0.08
Sulphadoxine-pyrimethamine, adult course 0.16 0.15 0.15 0.17
Sulphadoxine-pyrimethamine, child course 0.07 0.07 0.07 0.08
Antibiotics, adult course 0.16 0.15 0.15 0.17
Antibiotics, child course 0.16 0.15 0.15 0.17
Diagnostics training cost in US$ for health personnel per patient enrolled
Microscopy 0.10
Rapid diagnostic test 0.03
Household cost in US$ (over a period of 28 days from the first visit) &
Out-of-pocket expenditure, patient appropriately treated 3.12 0.00 0.00 38.74 (0.00; 1.99)
Out-of-pocket expenditure, patient inappropriately treated 2.26 0.00 0.00 21.46 (0.00; 2.78)
Opportunity cost of time lost, patient appropriately treated 5.80 4.94 0.00 19.75 (1.23; 8.64)
Opportunity cost of time lost, caregiver of patient inappropriately treated 3.20 2.47 0.00 11.11 (0.00; 6.17)
Opportunity cost of time lost, patient inappropriately treated 5.20 3.70 0.00 12.35 (3.70; 8.64)
Opportunity cost of time lost, caregiver of patient inappropriately treated 2.73 3.70 0.00 8.64 (0.00; 3.70)
# Incorporates the full cost of offering services at public health centres including prices of RDTs, microscopy consumables or drugs as well as personnel,
dispensing, utilities, and capital cost of buildings and equipment.
& Lost time valued at US$1.23 per day equal to GDP per capita per day in 2009 [34].
IQR = interquartile range.
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expected outcomes for RDT versus current diagnostic
method were expressed as monetary net benefits for a
specified value of willingness-to-pay (λ), the option with
the higher net benefits being the cost-effective for any
given set of randomly drawn input values. The model was
run for values of λ from $0 to $100 (in steps of $5). The
resultant output for each trial setting, i.e., the probability
of how often RDT or usual care is the cost-effective inter-
vention for each value of λ, is presented graphically as a
cost-effectiveness acceptability curve [39,40].
Figure 1 Decision tree for the malaria diagnostic method used in each of the study arms in two regions of Afghanistan, 2009.
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Scenario analysis
The context of extremely low prevalence in the northern
region of the study area (less than 1%) offered an oppor-
tunity to estimate the incremental costs of selected mal-
aria elimination efforts. In the northern region of the
study area, new microscopes and trained technicians
were introduced specifically to contribute to the elimin-
ation of malaria in the area. The decision model was
used to estimate the cost per malaria case appropriately
treated in the three settings compared with blanket
coverage of treatment with paracetamol (an antipyretic
drug) alongside no parasitological testing. Only costs
from a health sector perspective were included. In a sec-
ond scenario analysis, the model was used to examine
the replacement of chloroquine (used for the treatment
of vivax malaria) and ACT for treatment of falciparum
malaria, with ACT used for treating both vivax and fal-
ciparum malaria. Published trial reports of ACT versus
chloroquine to treat vivax show that vivax infections
treated with SP/artesunate (AS) or other ACTs would be
as good, or potentially superior to the standard treat-
ment with chloroquine alone [41,42]. This scenario was
considered because treating all malaria with ACT may
simplify treatment protocols for health workers and de-
emphasize the importance of high quality, differentiated
diagnosis. Microscopists can accurately identify malaria
parasites on blood smears, but it is less easy to ensure
correct species identification in low-endemic settings
with low parasite density infections [3,43]. Currently,
SP/AS is the recommended ACT in Afghanistan but this
drug may be replaced in the future if SP resistance is dem-
onstrated through molecular or in vivo monitoring. An
attractive alternative is dihydroartemisinin-piperaquine
(DHA-PPQ) [42], but this drug combination is consider-
ably more expensive. The decision model was therefore
used to also assess the impact of drug price variation by
modelling the use of more expensive ACT for treatment
of both P. vivax and P. falciparum.
Results
The results of the probabilistic cost-effectiveness ana-
lyses are presented in Table 4. In the moderate transmis-
sion eastern region, the societal cost per patient was
marginally lower in the RDT arm compared to the mi-
croscopy arm (US$9.5 versus US$9.8) but the effect in
terms of appropriately treated patients was higher in the
RDT arm than in the microscopy arm (83.7%, CI:
(82.0%; 85.3%) versus 76.3%, CI: (74.4%; 78.2%)). Since
the effect was higher and the cost was lower, diagnosis
by RDT is the dominant option compared to diagnosis
by microscopy from an economic perspective. In the low
transmission northern region with recently installed new
microscopes in health centres, the societal cost per pa-
tient was higher in the microscopy arm compared with
the RDT arm (US$20.6 versus US$13.5). The effect in
terms of the number of appropriately treated patients
was slightly higher in the RDT arm (80.2%, CI: (77.0%;
83.7%)) compared to the microscopy arm (76.2%, CI:
(72.4%; 80.0%)). Diagnosis by RDT was therefore domin-
ant from an economic perspective in the low transmis-
sion area. Finally, in the low transmission northern
region where the remaining health centres did not have
microscopes and relied on presumptive diagnosis, the
effect as measured by the proportion of appropriately
treated patients was much higher when diagnosing by
RDT as compared to presumptive diagnosis (65.9%, CI:
(60.6%; 71.1) versus 12.5%, CI: (9.1%; 16.1%)). The societal
cost per patient was slightly higher when using RDT diag-
nosis compared to presumptive diagnosis (US$13.2 versus
US$10.8) leading to an incremental cost-effectiveness ratio
(ICER) of US$4.5 per appropriately treated patient.
The cost-effectiveness planes (Figures 2, 3 and 4) show
results from the PSA and identify the extent of the uncer-
tainty in the incremental costs (y-axis) and in the incre-
mental outcomes (x-axis). In the moderate transmission
region where RDT diagnosis was compared to micros-
copy, estimates of the incremental effect are always posi-
tive, meaning that the percentage of appropriately treated
patients is always higher when using an RDT compared to
microscopy, with mean incremental effect of 7.4% (CI:
5.5%; 9.8%) (Figure 2). However, the incremental costs are
both positive and negative, suggesting that there is
uncertainty with regard to which diagnostic method has
the highest cost per patient although, on average, RDT
costs are lower with a mean incremental cost of -US0.3
(CI: −US$4.4; US$2.8). In the low transmission area
comparing RDT and microscopy diagnosis, incremental
societal costs are always negative so that societal cost per
patient in the RDT arm is always lower than in the
microscopy arm with mean incremental cost of -US7.1
(CI: −US$8.0; −US$6.0) (Figure 3). RDTs showed a better
effect in terms of the number of appropriately treated
patients in most iterations of the Monte Carlo simulation
although in a minority of these, microscopy had a higher
effect. The mean incremental effect was 4.0% (CI: −0.8%;
8.8%). While this suggested that no significant difference
could be demonstrated between RDT and microscopy,
adjusting for a range of factors including patient age and
health centre characteristics did result in a significantly
higher number of appropriately treated patients in the
RDT arm (see Table 1). In the low transmission region
where diagnosis was presumptive, the results of the PSA
show that the effects are always positive being situated to
the right of the origin with mean incremental effect of
53.4% (CI: 47.4%; 59.5%) (Figure 4). This means that there
is no uncertainty that using RDT diagnosis always led to
an improvement in the number of appropriately treated
patients compared to presumptive diagnosis. With respect
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Table 4 Cost per patient in US$, effects and incremental cost-effectiveness ratios (ICERs) of replacing current diagnostic methods by rapid diagnostic tests in
two regions of Afghanistan, cost in US$ (AFN50.33 = US$1), 2009
Moderate transmission region Low transmission region
Area with microscopes Area without microscopes
Microscopy arm RDT arm Microscopy arm RDT arm Clinical arm RDT arm
Appropriately treated patients in % (95% CI) 76.3 (74.4; 78.2) 83.7 (82.0; 85.3) 76.2 (72.4; 80.0) 80.2 (77.0; 83.7) 12.5 (9.1; 16.1) 65.9 (60.6; 71.1)
Cost per patient in US$ (95% CI):
Health sector cost 2.6 (2.6; 2.6) 2.6 (2.5; 2.6) 9.0 (9.0; 9.0) 1.9 (1.8; 1.9) 0.5 (0.5; 0.5) 1.8 (1.8; 1.8)
Household cost 7.2 (0.1; 37.6) 6.9 (0.1; 36.0) 11.6 (3.6; 28.4) 11.6 (3.4; 29.5) 10.3 (3.4; 23.6) 11.4 (3.6; 25.7)
Total societal cost 9.8 (2.7; 40.0) 9.5 (2.6; 40.5) 20.6 (12.5; 36.4) 13.5 (5.2; 30.3) 10.8 (3.9; 23.8) 13.2 (5.7; 28.3)
Incremental analysis (95% CI): Replace microscopy
diagnosis by RDT
Replace microscopy
diagnosis by RDT
Replace presumptive
diagnosis by RDT
Increase in patients appropriately treated in % 7.4 (5.0; 9.8) 4.0 (−0.8; 8.8) 53.4 (47.4; 59.5)
Incremental cost in US$, health sector perspective −0.0 (−0.0; −0.0) −7.1 (−7.1; −7.1) 1.3 (1.3; 1.3)
Incremental cost in US$, societal perspective −0.3 (−4.4; 2.8) −7.1 (−8.0; −6.0) 2.4 (−7.5; 15.7)
ICER in US$, health sector perspective Dominant Dominant 2.5
ICER in US$, societal perspective Dominant Dominant 4.5
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Figure 3 Cost-effectiveness plane of RDT diagnosis compared with microscopy diagnosis in a low transmission region of Afghanistan, 2009:
scatterplot of incremental societal costs in US$ and incremental effect of appropriately treated patients. Average incremental cost: −US$7.05,
average incremental effect: 0.04.
Figure 2 Cost-effectiveness plane of RDT compared with microscopy diagnosis in a moderate transmission region of Afghanistan, 2009:
scatterplot of incremental societal costs in US$ and incremental effect of appropriately treated patients. Average incremental cost: −US$0.32,
average incremental effect: 0.07.
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Figure 5 Cost-effectiveness acceptability curves for replacing microscopy diagnosis and presumptive diagnosis by RDT diagnosis in a moderate
and a low transmission region of Afghanistan, 2009.
Figure 4 Cost-effectiveness plane of RDT compared with presumptive diagnosis in a low transmission region of Afghanistan, 2009: scatterplot of
incremental societal costs in US$ and incremental effect of appropriately treated patients. Average incremental cost: US$2.38, average incremental
effect: 0.53.
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to incremental costs, there are both positive and negative
values meaning that there is uncertainty in the direction
of RDT versus presumptive costs with mean incremental
cost of US$2.4 (CI: −US$7.5; US$15.7).
The uncertainty displayed in these scatterplots may be
summarized as cost-effectiveness acceptability curves
[39,40] showing the probability that the introduction of
RDT diagnosis is a cost-effective intervention as a func-
tion of the decision maker’s willingness to pay (WTP)
for an additional appropriately treated patient (Figure 5).
In the moderate transmission area, if the WTP is US$5
per appropriately treated patient, the probability of RDT
diagnosis being the cost-effective intervention is 84%
increasing to 90% and above if the WTP is US$10 or
higher. Comparing RDT diagnosis to microscopy in the
low transmission region, there is no uncertainty that
RDT diagnosis is the cost-effective intervention since
the probability is 100% for any positive value of WTP up
to approximately US$330 and still 99% at a WTP of
US$500. Finally, introducing RDTs into health centres in
the low transmission area with currently only presump-
tive diagnosis would be cost-effective with a probability
of 56% if the WTP for an additional appropriately
treated patient was US$5 increasing to 77 and 98% if the
WTP was US$10 and US$30, respectively. In summary,
RDT diagnosis was found to have a high probability of
being a cost-effective intervention in all three settings
even at relatively low levels of WTP per appropriately
treated patient.
The results of the scenario analysis assessing the cost
per appropriately treated malaria patient are presented
in Table 5. In the low transmission setting with recently
installed microscopes, the incremental cost per add-
itional appropriately treated malaria patient after diagno-
sis by microscopy compared with blanket prescribing of
paracetamol to fever patients was US$1,102 - three times
the incremental cost of US$384 of diagnosis by RDT.
The incremental cost per appropriately treated malaria
patient was much lower in the moderate transmission
area in both the microscopy and RDT arms. In the low
transmission area where presumptive diagnosis is the
norm, this analysis was not performed since no malaria
cases were found.
The second scenario analysis examined replacing
chloroquine with ACT to treat all malaria cases (regard-
less of the infecting species), and then exploring the
effect of changes in the price of ACT. It was found that
increasing the ACT price will lead to RDTs becoming
increasingly cost-effective and eventually dominant in
the low transmission area with no current parasitological
test facilities. In the other two settings where RDTs are
already shown to be dominant, they remained dominant
as chloroquine was replaced by ACT and as the price of
ACT increased.
In all study arms in both regions, average household
costs constituted a significant share of societal costs
(57% or above). However, the level of household cost
varied widely across individuals in the sample, with the
majority experiencing no or very little household cost
related to the illness - 75% of participants reported hav-
ing no out-of-pocket expenditure for treatment seeking
and 65% of patients found that their illness prevented
their normal activities for two days or less. High costs in
a minority of households contributed to the high average
household costs (Table 4). When household costs were
excluded from the calculation to assess ICERs from a
health sector perspective the cost decreased, but this did
not change any of the conclusions from the main cost-
effectiveness analysis. In the setting with low transmission
and no parasitological diagnosis, the incremental cost
from a health sector perspective per additional appropri-
ately treated patient was US$2.5 if RDT diagnosis was
introduced instead of presumptive diagnosis (Table 4).
Discussion
These results support a strategy of introducing RDTs in
all three distinct settings included in the study as it is
cost-effective compared to the alternative. Most cost-
effectiveness studies of RDTs have used falciparum-
specific tests, while the present study used more expensive
bivalent tests to provide diagnosis of both P. falciparum
and P. vivax.
Table 5 Scenario analysis: Incremental cost-effectiveness ratio (ICER) for appropriately treated malaria patient from a
health sector perspective in US$ comparing microscopy and RDT diagnostic methods with paracetamol in two regions
of Afghanistan, 2009
Moderate transmission region Low transmission region
Area with microscopes Area without microscopes
Microscopy RDT Paracetamol Microscopy RDT Paracetamol Clinical RDT Paracetamol
Appropriately treated malaria patients (%) 21.03 21.01 0.00 0.78 0.38 0.00 0.00& 0.00& 0.00&
Health sector cost per patient in US$ 2.57 2.55 0.48 8.94 1.85 0.38 0.50 1.84 0.38
ICER, RDT versus paracetamol 9.85 384.20 -
ICER, microscopy versus paracetamol 9.94 1101.21 -
& No malaria cases.
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The sites show important differences in cost-effective-
ness in different settings of malaria transmission intensity.
In the moderate transmission area with long established
microscopes, RDTs dominated microscopy due to a higher
proportion of appropriately treated patients and, on aver-
age, at a slightly lower cost (although the difference was
modest). The results of the PSA showed that there was a
high probability that relying on RDTs for malaria diagno-
sis would be a cost-effective intervention even at relatively
low values of WTP (≤US$5). In the low transmission area
with newly established microscopy, RDTs had on average
a smaller advantage over microscopy in terms of appropri-
ately treated patients, but this was achieved at a much
lower cost. RDTs therefore dominated microscopy and the
PSA indicates that introducing RDTs would have a high
probability of being the cost-effective intervention. This
conclusion was driven by the high cost per microscopy-
based diagnosis, which was, in turn, caused by the use of
microscopes solely for the purpose of diagnosing malaria
in an area with very little malaria transmission and where
local elimination was the goal. This approach leaves mi-
croscopes and microscopists under-utilized. If the intro-
duction of new microscopes had incorporated the use of a
range of diagnostic tests rather than just malaria detection,
the cost advantage of RDTs would diminish. The sensitiv-
ity analysis carried out which assumed that the cost per
malaria slide was similarly low to that of the moderate
transmission area, where microscopes have a range of
functions, showed that RDTs would still dominate micros-
copy in the low transmission setting at the reduced mi-
croscopy cost. Finally, in the low transmission area with
no access to microscopy, there was a strong case for re-
placing presumptive diagnosis by RDT from a clinical
point of view as the proportion of appropriately treated pa-
tients in the trial increased five-fold. In this setting, RDTs
had a higher cost because of their associated commodity
prices, training and extra personnel time. However, be-
cause of the magnitude of the effect, the incremental cost
per additional appropriately treated patient was low:
US$4.5 from a societal perspective and US$2.5 from a
health sector perspective. If health policy makers are will-
ing to pay at least such an amount, then RDTs should be
introduced in this area to improve patient treatment.
Average household costs were found to be a significant
component of the cost of providing services in this study
although the burden varied widely across households in
the sample: the majority of households experienced no
cost while a minority had high costs. Household costs as
a proportion of total costs constituted upwards of 57%
in all study arms with both out-of-pocket expenditure
for healthcare seeking and opportunity cost of time lost
contributing to this high cost. This was in line with simi-
lar research in Africa where household costs also con-
tributed a high share of societal cost [24,44]. In the
moderate transmission region, appropriately treated pa-
tients had on average lower household cost than in-
appropriately treated patients, as also found in Ghana
[24]. The opposite was found in the low transmission re-
gion where inappropriately treated patients experienced
the lowest household cost (Table 3), a finding that may
be considered counterintuitive. One possible explanation
is the primary outcome of this study defined as ‘appro-
priate treatment for malaria’: a patient with a parasite-
positive reference slide receiving ACT/chloroquine or a
patient with a negative reference slide not receiving
ACT/chloroquine. Patients with true malaria correctly
treated with ACT or chloroquine have a high probability
of being cured and therefore have a low risk of incurring
additional household cost. Contrary to this, patients with
non-malarial causes of fever, as in the vast majority of
cases in low transmission settings, are more difficult to
diagnose and treat correctly. This could lead to more
frequent and costly additional healthcare seeking by
households. Since malaria prevalence was close to zero
in the low transmission region, patients suffered mainly
from fevers not caused by malaria where household cost
may be higher.
These high household costs did not influence the con-
clusions of the cost-effectiveness analysis of introducing
RDTs in the different settings. Leaving out all household
cost and calculating ICERs from a health sector perspec-
tive still supported RDTs replacing current diagnostic
techniques as the cost-effective intervention (Table 4).
Furthermore, the level of household cost depends on the
value assigned to lost time in this study. Sensitivity ana-
lysis using a minimum and maximum value per day of
US$0.50 and US$3.00, respectively, instead of US$1.23,
did not change the conclusions with respect to support-
ing RDTs as a cost-effective intervention in all study set-
tings. Other studies have examined the effect of clinician
compliance to the test result (including this trial). In
Tanzania, poor compliance to test results reduced the
cost-effectiveness of parasite-based diagnosis considerably
[20]. The data used in this study includes the non-
compliance to tests results by prescribers, which occurred
in 10-30% of malaria negative patients. Comparative cost-
effectiveness would be unlikely to change and there was
little difference in compliance between RDTs and micros-
copy [3].
Good quality microscopy has potential added value such
as the diagnosis of other conditions and clinical advantages
in assessing density of infection, confirming mixed infec-
tions, and assessing cure. In the eastern region, micro-
scopes and microscopists performed other tests, including
TB microscopy, but in the northern region in microscopy
health centres there were no additional benefits other than
malaria diagnosis. Thus, in the eastern region health
centres, only the ‘malaria-associated’ costs (time and
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materials) were allocated to microscopy to compare with
RDTs for malaria case management whilst in northern re-
gion health centres, the entire cost of microscopes and mi-
croscopists are attributed to malaria detection. Testing for
other diseases should be considered a separate intervention
and thus cost and effects of testing for other diseases were
excluded to make a direct comparison examining case
management only.
The results indicate that RDTs are cost-effective or
dominant in each setting. RDTs should therefore be used
in place of microscopy, if the microscopy is used solely
for malaria diagnosis. Even with multiple use micros-
copy, an alternative recommendation could be that the
laboratory primarily relies on RDTs, with the implicit
assumption that the freed capacity of the microscopy
and microscopists be used for other activities.
The analyses presented here estimate the cost-effective-
ness of the use of RDTs in an area of mixed malaria
endemicity outside Southeast Asia and the Pacific and
within a specific healthcare system and socio-economic
setting. However, the effects of RDTs are likely to be
generalizable to other areas of Afghanistan and the wider
region. The health service setting in which the trial took
place is a basic package of health services, replicated in all
areas of the country. The services provided by clinics in
Afghanistan and among regional neighbour countries may
be seen as similar at the primary care level. Malaria en-
demicity can also be seen as similar across the range of
malaria transmission intensity encountered in this study.
While the effect of RDTs is likely to be similar, the costs of
service provision and to the household are likely to differ
significantly across the region. Because of these differ-
ences, assessment of cost-effectiveness would be desirable
in each setting where RDTs are being considered for intro-
duction; the decision to switch to RDTs is potentially a
very expensive one.
As follow-up household costs were only collected on a
sub-sample of patients, a decision analytic modelling ap-
proach was chosen. This has the benefit of facilitating sce-
nario analysis and PSA, both of which were undertaken.
The PSA enabled uncertainty around the mean parame-
ters to be taken into account in the presentation of the re-
sults. Statistical analysis showed no covariate imbalances
at enrolment requiring adjustment and allowing adjust-
ment for clinic variation, as in the main trial results, indi-
cated a significantly stronger effect in only one region, all
other regions already showing a significant effect [3]. The
results are potentially conservative, which already show
RDTs to be cost-effective at low WTP thresholds and even
dominant in the comparison with microscopy.
Finally, health outcomes could have been extrapolated
beyond the trial period for patients in terms of cost per
Disability-Adjusted Life Year (DALY). In this trial, as
most patients were malaria negative, the impact on
DALYs between arms would be similar unless more in-
formation had been captured about the range and sever-
ity of the non-malarial causes of fever. Not enough is
known about complications from non-febrile illness but
almost all studies indicate that where malaria diagnosis
is introduced, use of anti-malarial treatment reduces at
the expense of increased (and probably unnecessary) use
of antibiotics in the majority of patients. A small group
of patients, however, may genuinely require antibiotic
treatment for potentially serious bacterial or parasitic in-
fections (such as brucellosis, coxiella, rickettsial diseases,
and leptospirosis). The identification of patients with
such conditions using point of care diagnostics is a
recognized priority for further research.
Conclusion
In this context, introducing malaria RDTs with a standard
training package is shown to be a desirable intervention
on cost-effectiveness grounds. In both the moderate and
low transmission areas, RDT diagnosis dominates micros-
copy and is therefore cost-effective. In settings currently
without parasitological diagnosis, the introduction of
RDTs leads to a large improvement in the proportion of
patients appropriately treated at a low cost, particularly
from a health sector perspective. The analyses presented
in this paper suggest that the RDT intervention provides
value for money in terms of appropriately treated febrile
patient in each of the trial settings.
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